Blog
After a 32% One-Year Run, an $8.2 Million Bet Signals Renewed Conviction in Non-U.S. Stocks
On January 23, FFG Partners disclosed a new position in the iShares MSCI ACWI ex U.S. ETF (NASDAQ:ACWX), acquiring 122,025 shares in an estimated $8.19 million transaction.
According to a SEC filing
This Fund Put $3.4 Million Into Navan Despite a 60% Post-IPO Drop
Lunate Capital disclosed a position in Navan (NASDAQ:NAVN) as of its January 23 SEC filing, acquiring 200,000 shares—an estimated $3.42 million trade based on quarterly average pricing.
According to
Netflix Shares Continue to Fall. Is It Time to Buy the Dip?
The share price of Netflix (NASDAQ: NFLX) continued its downward trend after the video streaming company issued cautious guidance when it recently reported its fourth-quarter results earlier this
Why One Fund Sold $5 Million of Chart Industries Stock
On January 23, Connecticut-based Iridian Asset Management disclosed a sale of 23,051 shares of Chart Industries (NYSE:GTLS), with an estimated transaction value of $4.67 million based on quarterly
ACWX vs. VT: Comparing Two of the Top Global ETFs
Both the Vanguard Total World Stock ETF (NYSEMKT:VT) and iShares MSCI ACWI ex U.S. ETF (NASDAQ:ACWX) aim to provide broad international equity exposure, but approach it differently. This comparison
Is Lucid Group Stock a Buy Now -- or an Easy "No" for 2026?
Lucid Group (NASDAQ: LCID) stock continues to be highly volatile early in 2026's trading. The electric vehicle (EV) company's share price is up roughly 8% year to date as of this writing, thanks to
Tractor Supply's Earnings Report Next Week Could Disappoint. But Are Shares a Buy Anyway?
Tractor Supply (NASDAQ: TSCO) reports its fourth-quarter results before market open on Jan. 29, and the headline numbers could land on the softer side of expectations. But even if this does happen
America Needs Rare Earth Magnets, and USA Rare Earth Is Positioning Itself to Fill the Gap
Critical minerals, and more specifically rare-earth magnets, are taking center stage in the U.S. as policymakers scramble to cut reliance on China, which has become a powerhouse for rare-earth
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
According to a Securities and Exchange Commission (SEC) filing dated January 20, 2026, Palisades Investment Partners, LLC reported initiating a new position in Travere Therapeutics (NASDAQ:TVTX).
3 Reasons to Buy TSMC Stock Like There's No Tomorrow
Will 2026 be another incredible year for artificial intelligence (AI)? So far, signals are all saying yes. The hyperscalers are planning to spend even more money than they did last year to build out
Does the 4% Rule Make Sense for Your Retirement Savings? Ask These 3 Questions to Find Out.
A lot of people work really hard to save money for retirement, but then struggle to actually start spending their savings. And a big reason boils down to a fear of running out.
The last thing you
Where Will Coca-Cola Stock Be in 3 Years?
It's impossible to overstate just how much Coca-Cola (NYSE: KO) dominates the worldwide market for soft drinks. It sells more than 200 different beverage varieties. Its products are available in
VWO vs. SPDW: How Does a Emerging Markets ETF Fair Against a Developed World Fund?
Both the Vanguard FTSE Emerging Markets ETF (NYSEMKT:VWO) and SPDR Portfolio Developed World ex-US ETF (NYSEMKT:SPDW) are broad international equity ETFs, but their focus differs by continent. This
Netflix Stock Tanks After Earnings: Warning Sign or Should You Ignore?
Netflix (NASDAQ: NFLX) stock was down as much as 7% in pre-market trading and off roughly 4% on Wednesday to around $83.40 per share -- a 52-week low. The catalyst is the streamer's fourth-quarter
Should You Dump Eli Lilly's Shares After This Setback?
Competition in the weight loss market is heating up. The two leaders, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), have robust pipelines, with several candidates recently approved or expected
Sandisk Stock Shows Why Investing Is Hard
Don't look now, but Sandisk (NASDAQ: SNDK) is the hottest stock in the S&P 500. Today's youth may be unaware that this company pioneered solid-state memory in the 1990s and went public over 30 years
Should You Buy Brookfield Asset Management While It's Below $55?
A good stock is an even better buy when a pullback has lowered its price. A discounted price resulting from a dip, however, doesn't necessarily make a stock worth buying.
That's the conundrum
The AI Energy Trade: Can Utility Stocks Be Winners in 2026? (NEE, SO, D)
In this video, Motley Fool contributors Jason Hall and Tyler Crowe make the case for Sun Belt electric utility stocks Dominion Energy (NYSE: D), NextEra Energy (NYSE: NEE), and Southern Co (NYSE:
The Ultimate Dividend Growth Stock to Buy With $1,000 Right Now
Dividend growth stocks can be powerful wealth-creating machines. Over the last 50 years, the average dividend grower in the S&P 500 has delivered a 10.2% annualized total return, according to Ned
These Crypto ETFs Offer High-Return Potential with Significant Risks
Both the VanEck Bitcoin ETF (NYSEMKT:HODL) and Bitwise Crypto Industry Innovators ETF (NYSEMKT:BITQ) offer access to the crypto economy, but they approach it in fundamentally different ways. HODL
2 Quantum Computing Stocks to Buy in Early 2026
Quantum computing is gradually evolving from a largely experimental technology toward commercialization. According to a forecast from the consultancy MarketsandMarkets, the global quantum computing
Could This Overlooked Company Be One of the Best Investments of the Next Decade?
It's the artificial intelligence (AI) giants that are capturing market attention these days, but these huge companies are mostly past their highest-growth days. Growth investors looking for serious
ISCG vs. RZG: How Do These Small Cap ETFs Measure Up to One Another?
The iShares Morningstar Small-Cap Growth ETF (NYSEMKT:ISCG) stands out for its ultra-low costs and broader portfolio, while the Invesco S&P SmallCap 600 Pure Growth ETF (NYSEMKT:RZG) brings a
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB), which rose 27% in 2025, nearly doubling the 16% gain
Defensive ETFs: KXI Charges Lower Fees, While FTXG Provides More Income
First Trust Nasdaq Food & Beverage ETF (NASDAQ:FTXG) and iShares Global Consumer Staples ETF (NYSEMKT:KXI) differ most on cost, performance, portfolio breadth, and sector concentration, with KXI